KBC Group NV Buys 1,820 Shares of Hologic, Inc. (NASDAQ:HOLX)

KBC Group NV raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 87,629 shares of the medical equipment provider’s stock after purchasing an additional 1,820 shares during the quarter. KBC Group NV’s holdings in Hologic were worth $7,138,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in HOLX. Price T Rowe Associates Inc. MD increased its position in shares of Hologic by 77.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after buying an additional 2,753,016 shares during the period. Swedbank AB purchased a new position in shares of Hologic during the 1st quarter worth approximately $120,827,000. Black Creek Investment Management Inc. raised its position in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after acquiring an additional 885,524 shares in the last quarter. Mackenzie Financial Corp raised its holdings in Hologic by 1,023.3% in the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock worth $66,506,000 after purchasing an additional 815,960 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Hologic during the second quarter valued at $39,427,000. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on HOLX shares. Raymond James upped their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research report on Tuesday, October 15th. Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. UBS Group boosted their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Performance

Shares of HOLX stock opened at $78.60 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average price of $80.71 and a 200-day moving average price of $78.25. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67. The firm has a market capitalization of $18.26 billion, a PE ratio of 23.60, a P/E/G ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.89 EPS. As a group, equities research analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.